Corazon (corsee) D. Sanders - 26 Nov 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Reporting relationship: Director
Issuer ticker: ONC
Reported as of: 26 Nov 2025
Net transaction value: -$477,763
SEC form: 4
Accepted by SEC: 01 Dec 2025, 16:57:56 UTC
Prior SEC filing: 09 Sep 2025
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Qing Nian, as Attorney-in-Fact

Key filing fact

Corazon (corsee) D. Sanders filed Form 4 for BeOne Medicines Ltd. (ONC) on 01 Dec 2025.

Key facts

This page summarizes Corazon (corsee) D. Sanders's Form 4 filing for BeOne Medicines Ltd. (ONC).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Dec 2025, 16:57.

Change

Previous filing in this sequence was filed on 09 Sep 2025.
Current net transaction value: -$477,763.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796536 Primary reporting owner

Sanders Corazon (Corsee) D.

Relationship: Director
Address: C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND
Signature: /s/ Qing Nian, as Attorney-in-Fact
Signature date: 01 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONC transaction

American Depositary Shares

Options Exercise

Transaction value: $417,772
Shares: +2,627
Change %
Price: $159.03
Shares after: 2,627
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F1

ONC transaction

American Depositary Shares

Sale

Transaction value: $620,185
Shares: -1,823
Change %: -69%
Price: $340.20
Shares after: 804
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F1, F2

ONC transaction

American Depositary Shares

Sale

Transaction value: $275,349
Shares: -804
Change %: -100%
Price: $342.47
Shares after: 0
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F1, F3

ONC holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 57,226
Date: 26 Nov 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONC transaction Derivative

Share Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -34,151
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 26 Nov 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 34,151
Exercise price: $12.23
Footnotes: F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each American Depositary Share represents 13 Ordinary Shares.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $340.04 to $340.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $342.42 to $342.675, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Footnote F4

The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

Footnote F5

The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors (the "Board") or otherwise ceases to serve as a director, unless the Board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.